HANSA BIOPHARMA

Investor Presentation

Erik Penser Company Day
Stockholm

August 24, 2023

Klaus Sindahl
VP, Head of Investor Relations

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Hansa Biopharma today

A successful track record and a promising future…

A validated technology

- Commercial stage biotech company
- Approval in kidney transplantation (EU)
- Market Access in 13 European markets
- PoC in autoimmune diseases
- Three partnerships in gene therapy

Broad clinical pipeline



- Imlifidase being investigated in seven ongoing clinical programs in transplantation and autoimmune disease
- Planned clinical study in gene therapy
- Next generation IgG antibody-cleaving enzymes program in phase 1

Skilled and experienced team

- A high-performance organization with 20 years on average in life science
- Purpose driven culture
- Headquartered in Lund, Sweden with 162 employees (June 2023)
- Operations in both EU and the US

Financial position

- Hansa is financed into 2025
- Market cap (USD): ~228m (July 2023)
- Listed on Nasdaq Stockholm
- 20,000 shareholders
- Foreign ownership make up ~43%

3

Imlifidase

a novel approach to eliminate pathogenic IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection



A unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



Broad pipeline with seven ongoing programs in clinical stage including three programs in late-stage development

Candidate/ Project	Indication	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients[1,2]	EU: Additional agreements around reimbursement / Post approval study to be completed by 2025
	US: Kidney transplantation in highly sensitized patients[1,2]	Completion of randomization (64 patients) H2 2023
	Anti-GBM antibody disease[3]	Complete enrollment (50 patients)
	Antibody mediated rejection in kidney transplantation (AMR)	Full data read out H2 2023
	Guillain-Barré syndrome (GBS)	Topline data H2 2023 / Comparative efficacy analysis 2024
	ANCA-associated vasculitis[4]	Complete enrollment (10 patients)
	Pre-treatment ahead of gene therapy in Duchenne (Partnered with Sarepta)	Initiate clinical study of imlifidase as pre-treatment in DMD 2023
	Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta)	Preclinical research
	Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio)	Preclinical research
	Pre-treatment ahead of gene therapy in Crigler-Najjar syndrome (Partnered with Genethon)	Preclinical research
HNSA-5487	Lead molecule from second-generation IgG antibody cleaving enzymes (NiceR)	Completion of phase 1 (H2 2023)



Completed | Ongoing | Planned | Post approval study running in parallel with commercial launch

[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund, Sweden
[4] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Imlifidase in kidney transplantation



HANSA BIOPHARMA

Idefirix® is the first and only approved drug in Europe for desensitization of highly sensitized kidney transplant patients

Between 80,000 and 100,000 kidney transplant patients are waiting for a new kidney in both Europe and the U.S. Availability of organs remain a big challenge since only 1 in 4 patients are offered access to a lifesaving transplantation, while many highly sensitized patients are unlikely to be transplanted even under current prioritization programs

Low complexity transplants → High complexity transplants

~70% of patients[1,2]	15-20% of patients[1,2]	10-15% of patients[1,2]
Non or less sensitized (cPRA < 20%)	Moderately sensitized (20% < cPRA < 80%)	Highly sensitized (cPRA > 80%)

Addressable market (annually)

4,000-6,000

split across Europe and the US

Patients that are likely to be transplanted with a compatible donor

Patients unlikely to be transplanted under current prioritization programs

First patient experiences with Idefirix in highly sensitized kidney patients post approval published

54-year-old man successfully transplanted at Vall d'Hebron, Barcelona after two failed transplantation attempts in the 90s and being on dialysis since 1984

Link article from Vall d'Hebron news forum August 25, 2022

29-year-old woman transplanted at Erasmus, Rotterdam after being dialysis dependent since 2016 and experiencing two graft losses

Link article in Amazing Erasmus from July 7, 2022

idefirix® imlifidase

[1] EDQM. (2020). International figures on donation and Transplantation 2019
[2] SRTR Database and individual assessments of allocation systems

7

Scaling Idefirix® globally as we transform the desensitization treatment landscape and advance a new way of transplanting patients

Key activity matrix

1 Build the foundation for Idefirix®

- ✓ Commercialize in early-launch countries
- ✓ Secure Market Access in key markets
- ✓ Ensure clinical readiness/KOL engagement
- ✓ Implement medical guidelines (ESOT and country specific guidelines)
- ✓ Increase awareness on unmet need
- ✓ Initiate post approval study in Europe
- ✓ Support patient and organ access

2 Expanding internationally

- Leverage experience to scale Idefirix in Europe
- Secure FDA approval and launch in the U.S.
- Geographical expansion beyond core markets
- Full marketing authorization in Europe

3 Potential label expansion

- Potentially expand into living donor transplantation
- Potentially expand into other solid organs

Commercial sales uptake

Eurotransplant has recently initiated a new desentization program for imlifidase-eligible patients

The Eurotransplant zone covers eight countries



New Pilot in the Acceptable Mismatch Priority Program

CURRENT
Acceptable Mismatch (AM) Program
Allocates organs to patients who are immunologically compromised because of current and/or historic HLA-sensitization

20 patients to be included in the Pilot program in rounds of five

NEW PILOT
Eurotransplant Desensitization Program
Imlifidase-eligible patients who are incompatible to a deceased donor

Inclusion criteria for new program

- No age limitation for patients
- Donor below 65 years
- A minimal waiting time of 3 years in the AM program
- Final transplant center CDC crossmatch must be negative.
- Informed consent form for a follow-up data

Idefirix receives provisional approval in Australia

First market to approve use in transplants from both living and deceased donors

Australian kidney disease and transplantation statistics

~15,200 patients suffer from ESRD and receive dialysis

1,338 patients were waitlisted for a kidney transplant from deceased donors in 2021

857 kidney transplantations were carried out in 2021

~21% of patients waitlisted have a cPRA score of 95 or higher

76/24 deceased vs living donor transplantations

Full approval in Australia will require submission to the TGA of further safety and efficacy data from studies that are currently underway (e.g. long-term follow-up, Post Approval Study and U.S ConfIdeS study)

Kidney transplantation landscape in Australia



Sources:

1. ANZDATA. The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) collects information about people receiving dialysis or kidney transplant for end-stage kidney disease in Australia and New Zealand.
2. ANZDATA 2022 Annual Report #45; available at: https://www.anzdata.org.au/report/anzdata-45th-annual-report-2022-data-to-2021/

Clinical development programs

HANSA BIOPHARMA

Autoimmune attacks

A result of when the body's immune system by mistake damages its own tissue

Blood
Autoimmune hemolytic anemia,
Immune thrombocytopenia

GI tract
Crohn's disease



Nerves
Guillain-Barré syndrome,
Myasthenia gravis

Lung
Wegner's granulomatosis





Over 100 different types of Autoimmune disorders

Skin
Psoriasis, Pemphigus



Brain
Multiple sclerosis,
Neuromyelitis optica

Thyroid
Hashimoto's disease,
Graves' disease



Kidney
Anti-GBM disease



Bone and muscle
Rheumatoid arthritis,
Dermatomyositis+ 32

Hansa's antibody cleaving enzyme technology

may have relevance in several autoimmune diseases where IgG plays an important role in the pathogenesis

Rapidly progressive glomerulonephritis

~1 000 patients*[1]

- Anti-GBM
- Lupus nephritis ~35 000*[2]
- ANCA-associated vasculitis ~325 000*[3]

Neurological disorders

- Myasthenia gravis ~210 000*[4]
- NMO ~20 000*[7]
- CIDP ~55 000*[6]
- GBS

~10 000 patients*[5]

Skin disorders

<1 000 patients*[8]

- EBA
- Pemphigus vulgaris ~40 000*[9]

Blood disorders

~1 000* patients[13]

- AHA
- WAHA ~95 000*[11]
- APS ~350 000*[12]
- HIT 0.1–5% of patients receiving therapeutic dose of heparin[14]
- ITP ~75 000*[10]

Clinical programs

Potential autoimmune indications (currently not pursued)

*Total disease populations in EU & US, based on prevalence and population data

CIDP: Chronic inflammatory demyelinating polyradiculoneuropathy
NMO: Neuromyelitis optica
EBA: Epidermolysis bullosa acquisita
ITP: Immune thrombocytopenia
WAHA: Warm antibody hemolytic anemia
APS: Antiphospholipid syndrome
AHA: acquired hemophilia A
HIT: Heparin-induced thrombocytopenia

[1]DeVrieze, B.W. and Hurley, J.A. *Goodpasture Syndrome*. StatPearls Publishing, Jan 2021. https://www.ncbi.nlm.nih.gov/books/NBK459291/ [accessed 2021-03-29]
[2]Patel, M et al. *The Prevalence and Incidence of Biopsy-Proven Lupus Nephritis in the UK*. Arthritis & Rheumatism, 2006.
[3]Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. *The Epidemiology of ANCA Associated Vasculitis in the U.S.: A 20 Year Population Based Study*. Arthritis Rheumatol. 2017;69.
[4]*Myasthenia Gravis*. National Organization for Rare Disorders, https://rarediseases.org/rare-diseases/myasthenia-gravis/ [accessed 2021-03-29]
[5]*Guillain-Barré syndrome*. Orpha.net, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=2103 [accessed 2021-03-29]
[6]*Chronic Inflammatory Demyelinating Polyneuropathy: Considerations for Diagnosis, Management, and Population Health*. The American Journal of Managed Care. https://www.ajmc.com/view/chronic-inflammatory-demyelinating-polyneuropathy-considerations-for-diagnosis-management-and-population-health [accessed 2021-03-29]
[7]Marrie, R.A. *The Incidence and Prevalence of Neuromyelitis Optica*. International Journal of MS Care, 2013 Fall: 113-118
[8]Mehren, C.R. and Gniadecki, R. *Epidermolysis bullosa acquisita: current diagnosis and therapy*. Dermatol Reports, 2011-10-05
[9]Wertenteil, S. et al. Prevalence *Estimates for Pemphigus in the United States*. JAMA Dermatol, May 2019: 627-629.
[10]*Immune Thrombocytopenia*. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/immune-thrombocytopenia// [accessed 2021-03-29]
[11]*Warm Autoimmune Hemolytic Anemia*. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/warm-autoimmune-hemolytic-anemia/ [accessed 2021-03-29]
[12]Litvinova, E. et al. *Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria*. Frontiers in Immunology, 2018-12-14.
[13]NORD, Acquired Hemophilia [accessed 2022-10-17], available at https://rarediseases.org/rare-diseases/acquired-hemophilia/
[14]Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. Vascular Medicine. 2020;25(2):160-173. doi:10.1177/1358863X19898253

New investigator-initiated phase 2 study in ANCA-associated vasculitis

- a group of autoimmune diseases characterized by inflammation of blood vessels with very few treatment options today

Incidences

~3 in 100,000 annually across EU/US of which 8-36% are estimated to have Acute Respiratory Distress Syndrome due to pulmonary hemorrhage[1,2]

Standard of Care

- Current protocol is Immunosuppression and Intensive support care

Indication

- Causes damage to small blood vessels in the body resulting in inflammation and damage to organs, such as the kidneys, lungs etc.[3]
- Progress of the disease results in end stage kidney disease in 25 percent of patients[5]
- Most severe cases involving lungs lead to respiratory failure[4]
- Few treatment options today



Vasculitis means inflammation of blood vessels

The investigator-initiated trial (IIT) is sponsored by Charité Universitätsmedizin, Berlin

Study design

- Single arm, single center, phase 2 study with the primary objective to evaluate efficacy and safety on top of SoC
- 10 patients with severe ANCA-associated vasculitis and Acute Respiratory Distress Syndrome will be treated with imlifidase on top of SoC
- First patient treated Q2 2023
- Trial led by Dr. Adrian Schreiber and Dr. Philipp Enghard at Charité

1. Berti A, et al. Arthritis Rheum atol. 2017;69.
2. Rathmann J, et al. RMD Open. 2023;9:e002949.
3. Falk RJ, Jennette JC. The New England journal of medicine. 1988;318(25):1651-7.
4. Flossmann O, et al. Annals of the rheumatic diseases. 2011;70(3):488-94.
5. Booth AD, et al. American journal of kidney diseases. 2003;41(4):776-84.

Gene Therapy



HANSA BIOPHARMA

Neutralizing antibodies (Nabs) are immunological barriers in gene therapy; imlifidase may potentially eliminate Nabs

Between approximately 5%-70%[1,2] of patients considered for gene therapy treatment carry neutralizing anti-AAV antibodies forming a barrier for treatment eligibility

1 Antibodies prevent effective transfer of healthy gene sequence and can be a safety concern



2 Imlifidase is a unique IgG antibody-cleaving enzyme that cleaves IgG at the hinge region with extremely high specificity



3 The idea is to eliminate the neutralizing antibodies as a pre-treatment to enable gene therapy



[1] Boutin (2010)
[2] Kruzik (2019)

Global exclusive agreements with three partners in gene therapy

To develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications

Partner	Access to key resources	Indication exclusivity	Collaborative research, development and commercialization
SAREPTA THERAPEUTICS	▪ World leader within gene therapy targeted at muscular dystrophies ▪ Pre-clinical and clinical plan ▪ Regulatory ▪ Promotion ▪ FDA approval in 4–5-year-old kids suffering with DMD	**Duchenne Muscular Dystrophy (DMD)** 1/3,500 to 5,000 male births worldwide	Antibody cleaving enzyme technology ✓ → Preclinical Development ✓ → Planned Clinical Development → Regulatory Approvals → Commercialization
		Limb-Girdle Muscular Dystrophy Global prevalence of ~1.6 per 100k individuals	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development → Regulatory Approvals → Commercialization
AskBio™	▪ Early innovator in gene therapy ▪ Conducts pre-clinical and clinical trials (Phase 1/2)	**Pompe disease** Approximate incidence is 1 per 40,000 births, or ~200 per year in the US + EU	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development Phase 1/2 study (feasibility)
GENETHON CURE THROUGH INNOVATION	▪ A pioneer in the discovery and development of gene therapies ▪ Conducts pre-clinical and clinical trials (Phase 1/2)	**Crigler-Najjar syndrome** Approximately incidence is 0.6-1 case per one million people or 600 patients in Europe and the U.S	Antibody cleaving enzyme technology ✓ → Preclinical Development → Clinical Development Phase 1/2 study (feasibility)

Exclusive option for AskBio to negotiate a potential full development and commercialization agreement

The initial agreement is focused on research and development

The companies will consider a subsequent agreement for commercialization at a later stage

Duchenne muscular dystrophy (DMD) is progressive and causes irreversible muscle damage and loss of function

Incidences

1 in **3,500** to **5,000**
male births worldwide

~14% have pre-existing IgG antibodies to rh74

High unmet need

- DMD is a rare, fatal neuromuscular genetic disease
- Muscle weakness noticeable by age 3-5, and most patients use a wheelchair by the time they are 12, many require respiratory aid by late teens.
- Life expectancy 26-30 years

DMD signs at early age, with most patients using a wheelchair by age 12



Source:
Sarepta Therapeutics, https://www.sarepta.com/ [Accessed 2023-06-13]

Our unique antibody cleaving enzyme technology may have relevance across a range of indications

Targeting rare IgG mediated diseases

Auto-immune diseases

Anti-GBM disease paves the way for development in other autoimmune diseases

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin and blood disorders

New therapies and oncology

IgG-cleaving enzymes to enable or even potentiate cancer therapy

- Allogenic stem cell (bone marrow) transplantation (HSCT)



Transplantation

Shaping a new standard for desensitization will help enable new indications in transplantations

- Antibody mediated rejection (AMR) in kidney transplantation
- Other transplantation types

Gene therapy

Exploring opportunities in gene therapy

- Encouraging preclinical data published in Nature
- Validation through collaborations with Sarepta, AskBio, and Genethon
- Wide indication landscape beyond

Regulatory approval (conditional) | Clinical development | Planned clinical trial | Partnership (preclinical development) | Preclinical development | Potential indications (currently not pursued)


HANSA
BIOPHARMA

Achieved and upcoming milestones

2023

H1 2023

- ✓ **U.S. ConfIdeS (Kidney tx) Phase 3:** Complete enrollment
- ✓ **Anti-GBM disease Phase 3:** First patient enrolled
- ✓ **GBS Phase 2:** Complete enrollment
- ✓ **ANCA-associated vasculitis Phase 2:** First patient enrolled
- ✓ **HNSA-5487 (Lead NiceR candidate):** Initiate Phase 1 study
- ✓ **Genethon Crigler-Najjar:** Initiate preclinical study with imlifidase prior to GNT-0003

H2 2023

- **U.S. ConfIdeS (Kidney tx) Phase 3:** Complete randomization
- **GBS Phase 2:** First data readout
- **AMR Phase 2:** Full data readout
- **Long-term follow-up (Kidney tx):** 5-year data readout
- **Sarepta DMD pre-treatment Phase 1b:** Commence clinical study
- **HNSA-5487 (Lead NiceR candidate):** Completion of Phase 1 study

2024

- **U.S. ConfIdeS (Kidney tx) Phase 3:** BLA submission
- **GBS Phase 2:** Outcome of the comparative efficacy analysis to IGOS data
- **Genethon Crigler-Najjar Phase 1/2:** Initiate clinical study with imlifidase prior to GNT-0003

Contact our Investor Relations and Corporate Affairs team

Contact

Klaus Sindahl

VP, Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs

VP, Global Corporate Affairs

Mobile: +1 (484) 319 2802

E-mail: stephanie.kenney@hansabiopharma.com

Calendar and events

Aug 31, 2023	HC Andersen – Life Science seminar (virtual)
Sept 11, 2023	HC Wainwright Annual Global Investment Conference, NYC
Sept 11, 2023	MorganStanley Global Healthcare Conference, NYC
Sept 14, 2023	Pareto Annual Healthcare Conference, Stockholm
Sept 14, 2023	Erik Penser Company Day, Malmö
Oct 2, 2023	Redeye: Autoimmune and inflammatory disease, Stockholm
Oct 5-6, 2023	Cowen US non-deal road show
Oct 12, 2023	Redeye: Afterwork, Malmö
Oct 19, 2023	**Interim Report for January-September 2023**
Nov 21, 2023	SEB Healthcare Seminar 2023, Stockholm
Nov 22, 2023	Ökonomisk Ugebrev Life Science event, Copenhagen